Jugular paraganlioma is a benign, slow-growing tumor originating from the paraganglion cells and it is associated with catecholamine secretion. Paragangliomas can secrete Interleukin-6 (IL-6) and present as a systemic inflammatory syndrome; these characteristics have not been previously associated with jugular paragangliomas. A 63-year-old man with a jugular tumor in the skull base was referred to our hospital for an evaluation of pyrexia, back pain, and acute inflammation. His serum IL-6 level was elevated on admission and it decreased after radiotherapy. This is the first known case of a jugular paraganglioma exhibiting systemic inflammatory syndrome.
Introduction
Jugular paraganlioma is a benign, slow-growing tumor arising from the paraganglion cells in many head and neck sites. It comprises tumors of the carotid body and glomus jugulare and its typical manifestations involve auditory and lower cranial nerve deficits due to a mass effect. The diagnosis of a jugular paraganglioma in the skull base may sometimes be delayed because of its insidious onset (1) (2) (3) (4) (5) (6) . Paragangliomas may be hyperfunctional, with approximately 4% showing catecholamine secretion (1) (2) (3) (4) (5) . Paragangliomas sometime secrete various neuropeptide hormones, such as adrenocorticotropic hormone, and inflammatory cytokines, such as interleukin-6 (IL-6). Systemic inflammatory syndrome, including pyrexia, is a rare presentation in patients with paraganglioma (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . We herein report the first known case of a jugular paraganglioma exhibiting systemic inflammatory syndrome.
Case Report
A 63-year-old man was referred to our hospital for an evaluation of pyrexia, back pain, and acute inflammation.
He had undergone transvascular embolization of a large inoperable glomus jugular tumor 18 years prior to presentation and had a 5-year history of episodic pyrexia and back pain, and his body weight had decreased by 14 kg, i.e., from 62 kg to 48 kg over a 3-year period. One year prior to presentation, an elevation in the C-reactive protein level (4.39 mg/ dL) was detected during a routine health checkup. Three weeks prior to presentation, he developed pyrexia, and back pain with a marked elevation in the C-reactive protein level (22.9 mg/dL). Under a putative diagnosis of polymyalgia rheumatica, he was prescribed prednisolone (20 mg/day) and was eventually referred to our hospital after showing no improvement in the inflammation.
On admission, he seemed uncomfortable and cachexic (height, 1.67 m; weight, 51 kg). His blood pressure was 120/64 mmHg, heart rate was 78 beats/min, and body temperature was 36.6°C. A soft, non-tender left cervical mass was observed on physical examination. Neurological findings included loss of pain and touch sensation on the left side of his face, difficulty in wrinkling the brows, and reduced hearing in the left ear. The uvula showed a rightward shift and his tongue deviated to the left. These findings suggested deficits of multiple cranial nerves (V, VI, VII, VIII, IX, XI, and XII). Laboratory tests indicated chronic inflamDepartment of General Internal Medicine, Hiroshima University Hospital, Japan 119 mm/h mation ( Table 1) . The results of blood culture and autoantibody tests were negative. The adrenocorticotropic hormone and catecholamine levels were within the normal limits. The laboratory findings and thoracoabdominal computed tomography (CT) with contrast medium showed no evidence of either a urinary tract infection or any neoplasm. Magnetic resonance imaging (MRI) demonstrated an enhanced tumor extending from the left temporal lobe to the cerebellum and internal jugular vein. Positron emission tomography/CT identified a mass in the left skull base close to the left jugular vein, with no significant uptake elsewhere (Fig. 1) . The radiological findings, including a "salt and pepper appearance" observed using MRI, were consistent with those of a jugular paraganglioma. Surgical resection was not performed because of the high risk of intraoperative morbidity and mortality. He received 50.4 Gy of external radiotherapy on the left side of his neck and the left skull base over a 5-week period. MRI at a 5-month follow-up demonstrated a slight involution of the skull base with the marked shrinkage of the involved part of the left internal jugular vein. Pyrexia was relieved by loxoprofen during the first few months. After external radiotherapy was started, he reported an improvement in both the pyrexia and back pain (Fig. 2) , thus suggesting that the improvements in symptoms and inflammation were due to tumor shrinkage. To determine the cause of systemic inflammation, we measured the serum IL-6 level; IL-6 induces the production of acute-phase proteins in paraneoplastic syndrome. On admission, his serum IL-6 level was 94.2 pg/mL, which is approximately 10 times the normal upper limit ( 9.96 pg/mL). After radiotherapy, the serum IL-6 and C-reactive protein levels decreased to 20.3 pg/mL and 6.97 mg/dL, respectively.
Discussion
The present case illustrates an important clinical consideration. Although a jugular paraganglioma typically presents as an asymptomatic cervical mass which may be associated with lower cranial nerve deficits (1) (2) (3) (4) (5) , it can cause systemic inflammatory syndrome which appears as paraneoplastic syndrome. Although pyrexia is not a typical manifestation of a paraganglioma, Ghoreishi et al. (6) reported the case of a 78-year-old woman with a carotid body paraganglioma presenting with fever. In another case, a pulmonary glomus tumor was discovered after thoracoscopic surgery in a 28-year-old man presenting with hyperpyrexia, weight loss, and an elevated C-reactive protein level (17.8 mg/dL) (18) . The symptoms of both cases resolved after tumor resection, but the IL-6 level was not measured (6, 18) . IL-6 is a major inflammatory cytokine that modulates transcription to stimulate the synthesis of acute phase proteins, such as C-reactive protein, while inhibiting albumin synthesis (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . IL-6-producing tumors associated with paraneoplastic syndrome have been reported in 11 paraganglioma patients, including 10 with pheochromocytomas and 1 with a malignant paraganglioma (Table 2) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Cases with IL-6-producing pheochromocytomas are characterized by the presence of pyrexia as well as systemic inflammatory syndrome. Omura et al. (9) reported a patient with a malignant paraganglioma producing both IL-6 and adrenocorticotropic hormone, but no inflammatory signs. In some case reports (7, 9, 12, 15) , IL-6 overproduction was demonstrated by immunohistochemical analyses and it was also observed in cultured tumor cells. Although the underlying mechanisms remain unclear, IL-6 overproduction can be ascribed directly to the tumor or indirectly to tumoral production as a consequence of the high levels of circulating norepinephrine (13, 15) .
In conclusion, we herein reported a patient with jugular paraganglioma exhibiting systemic inflammatory syndrome. Paraneoplastic syndrome should therefore be included in the differential diagnosis in cases with paragangliomas and systemic inflammation.
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